BI-PROFENID 150mg scored tab.

البلد: مصر

اللغة: الإنجليزية

المصدر: EDA (Egyptian Drug Authority)

متاح من:

SANOFI AVENTIS-FRANCE

جرعة:

150 mg

الشكل الصيدلاني:

tablet

الوحدات في الحزمة:

20 tablets

المصنعة من قبل:

SANOFI AVENTIS-EGYPT

تاريخ الترخيص:

2002-05-21

نشرة المعلومات

                                19/07/2018 12:04 - VISTAlink folder 3522968 - Page 1/2 1.NAME OF THE MEDICINE
BI-PROFENID 150 MG, SCORED TABLET
2.QUALITATIVE AND QUANTITATIVE COMPOSITION
White Layer( immediate release):
Ketoprofen............................................................
75, 00 mg
Yellow Layer(modified release ):
Ketoprofen............................................................
75.00 mg
For a scored tablet.
Excipient with a discernable effect: lactose
For a full list of excipients, see section 6.1.
3.PHARMACEUTICAL FORM
Scored tablet.
4.CLINICAL DATA
4.1 THERAPEUTIC INDICATIONS
They are derived from the analgesic and anti-inflammatory activity of
Bi-Profenid, The importance of the manifestations of intolerance to
which the
medicine gives rise, and its place in the range of anti-inflammatory
products
currently available.
They are limited, in adults and children from 15 years, to:
•Long-term symptomatic treatment:
oChronic inflammatory rheumatism conditions including rheumatoid
arthritis, ankylosing spondylitis (or related syndromes such as
Fiessinger-
Leroy-Reiter syndrome and psoriatic arthritis),
oOf certain painful and disabling arthroses.
•short-term symptomatic treatment of acute attacks:
oAbarticular rheumatism such as scapulo-humeral periarthritis,
tendonitis,
bursitis,
oMicrocrystalline arthritis,
oArthroses,
oLumbago,
oRadiculalgies,
oAcute benign post-traumatic affections of the musculoskeletal system.
•Treatment of the migraine crisis with or without aura.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
METHOD OF ADMINISTRATION: Orally.
The tablets should be swallowed as they are, with a large glass of
water.
DOSAGE
•Rheumatology:
oLong-term symptomatic treatment: 150 mg per day, either one
single-dose
tablet or two doses of half-tablets.
oShort-term symptomatic treatment of acute attacks: 300 mg per day, ie
two
tablets of 150 mg in 2 divided doses.
•Treatment of the migraine crisis:
It is recommended to take the treatment as early as possible, from the
beginning of the migraine crisis.
Begin the treatment 
                                
                                اقرأ الوثيقة كاملة
                                
                            

مستندات بلغات أخرى

نشرة المعلومات نشرة المعلومات العربية 27-04-2024

تنبيهات البحث المتعلقة بهذا المنتج

عرض محفوظات المستندات